Western Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-11,265
Closed -$365K 618
2022
Q3
$365K Sell
11,265
-270
-2% -$9.91K 0.02% 584
2022
Q2
$362K Sell
11,535
-9,484
-45% -$332K 0.02% 555
2022
Q1
$966K Buy
21,019
+9,710
+86% +$463K 0.05% 341
2021
Q4
$692K Buy
+11,309
New +$782K 0.07% 267
2021
Q2
$910K Sell
9,856
-304
-3% -$25.8K 0.09% 227
2021
Q1
$901K Buy
10,160
+4,154
+69% +$412K 0.12% 180
2020
Q4
$560K Buy
6,006
+1,050
+21% +$83.7K 0.08% 233
2020
Q3
$316K Buy
+4,956
New +$290K 0.05% 327

Other funds holding ARKG

Western Wealth Management's ARKG Position: Q4 2022 in Review

Western Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2022, closing a stake of 11,265 shares — an estimated $365K sold.

Western Wealth Management first reported a position in ARKG in Q3 2020 and held it in 8 quarters. The position peaked at $966K in Q1 2022. 319 funds tracked by Wall St. Rank hold ARKG as of Q4 2022.

  • Western Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2022 after selling out during the quarter.
  • Western Wealth Management sold 11,265 ARK Genomic Revolution ETF shares in Q4 2022, an estimated $365K.
  • Western Wealth Management first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 8 quarters.
  • Western Wealth Management's ARK Genomic Revolution ETF position peaked at $966K in Q1 2022.
  • 319 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2022.

Based on Western Wealth Management's 13F filing for Q4 2022, filed 3 Feb 2023.